All In Biotech

Drug Trial Radar · NCT02122471

12-Week Study of Plecanatide for CIC (The National CIC3 Study)

A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation

Last checked: Nov 20, 2026Latest source record: May 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,410 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,410

Actual

Start

Apr 2014

Primary completion

May 2015

Study completion Jul 2015

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Apr 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.

Conditions

  • Chronic Idiopathic Constipation

Interventions

  • PlecanatideDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Durable Overall CSBM Responders, Mean Replacement ApproachTime frame: 12-Week Treatment Period

Locations

167 sites in 1 country. Site status is shown where the registry gives one.

  • Synergy Research Site

    Anniston, Alabama

  • Synergy Research Site

    Huntsville, Alabama

  • Synergy Research Site

    Chandler, Arizona

  • Synergy Research Site

    Goodyear, Arizona

  • Synergy Research Site

    Tucson, Arizona

  • Synergy Research Site

    Tucson, Arizona

  • Synergy Research Site

    Tucson, Arizona

  • Synergy Research Site

    Tucson, Arizona

  • Synergy Research Site

    Tucson, Arizona

  • Synergy Research Site

    Anaheim, California

  • Synergy Research Site

    Artesia, California

  • Synergy Research Site

    Carmichael, California

  • Synergy Research Site

    Corona, California

  • Synergy Research Site

    Encino, California

  • Synergy Research Site

    Garden Grove, California

  • Synergy Research Site

    Garden Grove, California

  • Synergy Research Site

    Glendale, California

  • Synergy Research Site

    La Mirada, California

  • Synergy Research Site

    Laguna Hills, California

  • Synergy Research Site

    Los Angeles, California

  • Synergy Research Site

    Los Angeles, California

  • Synergy Research Site

    Newport Beach, California

  • Synergy Research Site

    Oceanside, California

  • Synergy Research Site

    Orange, California

  • Synergy Research Site

    Sacramento, California

  • Synergy Research Site

    Sacramento, California

  • Synergy Research Site

    San Bernardino, California

  • Synergy Research Site

    San Diego, California

  • Synergy Research Site

    Upland, California

  • Synergy Research Site

    Ventura, California

  • Synergy Research Site

    Denver, Colorado

  • Synergy Research Site

    Littleton, Colorado

  • Synergy Research Site

    Stamford, Connecticut

  • Synergy Research Site

    Aventura, Florida

  • Synergy Research Site

    Boynton Beach, Florida

  • Synergy Research Site

    Bradenton, Florida

  • Synergy Research Site

    Brandon, Florida

  • Synergy Research Site

    Brooksville, Florida

  • Synergy Research Site

    Clearwater, Florida

  • Synergy Research Site

    DeLand, Florida

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.